May Daher
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
Adoptive cell therapies (ACT) leverage tumor-immune interactions to cure cancer. Despite promising phase I/II clinical trials of chimeric-antigen-receptor natural killer (CAR-NK) cell therapies, molecular mechanisms and cellular properties required to achieve clinical benefits in broad cancer spectra remain underexplored. While in vitro and in vivo experiments are required in this endeavor, they are typically expensive, laborious, and limited to targeted investigations. Here, we present ABMACT (Agent-Based Model for Adoptive Cell Therapy), an in silico approach employing agent-based models (ABM) to simulate the continuous course and dynamics of an evolving tumor-immune ecosystem, consisting of heterogeneous “virtual cells” created based on knowledge and omics data observed in experiments and patients. Applying ABMACT in multiple therapeutic context indicates that to achieve optimal ACT efficacy, it is key to enhance immune cellular proliferation, cytotoxicity, and serial killing capacity. With ABMACT, in silico trials can be performed systematically to inform ACT product development and predict optimal treatment strategies.
Year:
2025
Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell activity, with costimulatory signals being a key component. Yet, the impact of costimulatory domains on the downstream signaling and subsequent functionality of CAR-engineered natural killer (NK) cells remains largely unexplored. Here, we evaluated the impact of various costimulatory domains on CAR-NK cell activity, using a CD70-targeting CAR. We found that CD28, a costimulatory molecule not inherently present in mature NK cells, significantly enhanced the antitumor efficacy and long-term cytotoxicity of CAR-NK cells both in vitro and in multiple xenograft models of hematologic and solid tumors. Mechanistically, we showed that CD28 linked to CD3ζ creates a platform that recruits critical kinases, such as lymphocyte-specific protein tyrosine kinase (LCK) and zeta-chain-associated protein kinase 70 (ZAP70), initiating a signaling cascade that enhances CAR-NK cell function. Our study provides insights into how CD28 costimulation enhances CAR-NK cell function and supports its incorporation in NK-based CARs for cancer immunotherapy. Significance: We demonstrated that incorporation of the T-cell–centric costimulatory molecule CD28, which is normally absent in mature natural killer (NK) cells, into the chimeric antigen receptor (CAR) construct recruits key kinases including lymphocyte-specific protein tyrosine kinase and zeta-chain-associated protein kinase 70 and results in enhanced CAR-NK cell persistence and sustained antitumor cytotoxicity.
Year:
2024
Collaborators (16)
Janos Roszik
The University of Texas MD Anderson Cancer Center
Navin Varadarajan
Professor
University of Houston
Elizabeth Shpall
Department Chair ad interim
The University of Texas MD Anderson Cancer Center
Alexander Biederstädt
Physician Scientist and Junior Group Leader
Technical University of Munich
Francisco Vega
Professor/Chief Lymphoma Section
The University of Texas MD Anderson Cancer Center
Katayoun Rezvani
The University of Texas MD Anderson Cancer Center
Stefano Casarin
Assistant Professor
Houston Methodist
Ye Li
Assistant Professor
The University of Texas MD Anderson Cancer Center
Hind Rafei
Assistant Professor of Medicine
The University of Texas MD Anderson Cancer Center
Joseph D. Khoury
University of Nebraska Medical Center
Rafet Basar
Assistant Professor
The University of Texas MD Anderson Cancer Center
Paul Lin
Assistant Professor
The University of Texas MD Anderson Cancer Center
Pinaki Banerjee
Assistant Professor, Director: Adoptive Cell Therapy Platform Research
The University of Texas MD Anderson Cancer Center
Pei Lin
Professor
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Maria Gabriela Raso
Assistant Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.